An open-label, extension, phase III study to evaluate the long-term safety and efficacy of MRA [tocilizumab] in patients with RA [rheumatoid arthritis] who participated in Study MRA012JP.
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2013
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 29 Dec 2009 Actual patient number added (241) as reported by ClinicalTrials.gov.
- 29 Dec 2009 Actual end date (June 2009) added as reported by ClinicalTrials.gov.
- 29 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.